Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Shen, Yun ^a   Ma, Xiaojing ^a   Zhou, Jian ^a   Pan, Xiaoping ^a   Hao, Yaping ^a   Zhou, Mi ^a   Lu, Zhigang ^a   Gao, Meifang ^a   Bao, Yuqian ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Coronary artery disease; Fibroblast growth factor 21; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; TRIACYLGLYCEROL;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84883118811     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-124     Document Type: Article

References (26)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000, 1492:203-206. 10.1016/S0167-4781(00)00067-1, 10858549.
2. Li H, Zhang J, Jia W. Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med 2013, 7:25-30. 10.1007/s11684-013-0244-8, 23358894.
3. Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012, 97:2143-2150. 10.1210/jc.2012-1221, 22438225.
4. Semba RD, Sun K, Egan JM, Crasto C, Carlson OD, Ferrucci L. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012, 97:1375-1382. 10.1210/jc.2011-2823, 3319186, 22344195.
5. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027. 10.1210/en.2008-0816, 18687777.
6. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940. 10.1016/j.jhep.2010.05.018, 20675007.
7. Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J, Rissanen A, Suomalainen A, Pietilainen KH. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011, 96:E351-E355. 10.1210/jc.2010-1326, 21123446.
8. Monsour HP, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease-its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J 2013, 8:21-25.
9. Jian-Gao F, . Chinese Liver Disease Association Guidelines for management of nonalcoholic fatty liver disease: An updated and revised edition. Zhonghua Gan Zang Bing Za Zhi 2010, 18:163-166. (in Chinese), Chinese Liver Disease Association.
10. Judkins MP. Percutaneous transfemoral selective coronary arteriography. Radiol Clin North Am 1968, 6:467-492.
11. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:390-419. (in Chinese), Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.
12. Yang G, Fan L, Tan J, Qi G, Zhang Y, Samet JM, Taylor CE, Becker K, Xu J. Smoking in china: findings of the 1996 national prevalence survey. JAMA 1999, 282:1247-1253. 10.1001/jama.282.13.1247, 10517427.
13. Gorar S, Culha C, Uc ZA, Dellal FD, Serter R, Aral S, Aral Y. Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol 2010, 26:819-826. 10.3109/09513590.2010.487587, 20486877.
14. Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lossner U, Bluher M, Stumoll M, Fasshauer M. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010, 59:33-37. 10.1016/j.metabol.2009.07.003, 19699495.
15. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol 2009, 71:369-375.
16. An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, Kim DJ, Lee KW. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012, 96:196-203. 10.1016/j.diabres.2012.01.004, 22293928.
17. Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y, Xiang K, Xu A, Jia W. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol 2013, 58:557-563. 10.1016/j.jhep.2012.10.029, 23142063.
18. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010, 29:e15534.
19. Lee Y, Lim S, Hong ES, Kim JH, Moon MK, Chun EJ, Choi SI, Kim YB, Park YJ, Jang HC, Choi SH. Serum FGF21 concentration is associated with hypertriglyceridemia, hyperinsulinemia and pericardial fat accumulation, independently of obesity but not with current coronary artery status. Clin Endocrinol 2012, Epub ahead of print.
20. Cheng X, Zhu B, Jiang F, Fan H. Serum FGF-21 levels in type 2 diabetic patients. Endocr Res 2011, 36:142-148. 10.3109/07435800.2011.558550, 21973233.
21. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamytransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009, 94:2151-2156. 10.1210/jc.2008-2331, 19318452.
22. Iglesias P, Selgas R, Remero S, Diez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 2012, 167:301-309. 10.1530/EJE-12-0357, 22740503.
23. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol 2012, 11:61. 10.1186/1475-2840-11-61, 3471007, 22676459.
24. Kawamoto R, Kohara K, Kusunoki T, Tabara Y, Abe M, Miki T. Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol 2012, 11:117. 10.1186/1475-2840-11-117, 3499385, 23020992.
25. Dostalova I, Haluzikova D, Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physio Res Acad Sci Bohem 2009, 58:1-7.
26. Lu Y, Liu JH, Zhang LK, Du J, Zeng XJ, Hao G, Huang J, Zhao DH, Wang GZ, Zhang YC. Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cell. Chin Med J 2010, 123:3417-3422.